| 摘要 |
The disclosure relates to a pharmaceutical formulation comprising: (a) pentosan polysulfate (PPS) or a salt thereof, and (b) a buffer, which preferably comprises at least one of citrate, sodium hydroxide/levulinic acid, acetate, bicarbonate, bisulfite, sodium hydroxide/glycine, and phosphate,wherein the formulation is stable without refrigeration and wherein the formulation is substantially free of brown impurities after terminal sterilization.
|
